IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Global Retirement Partners LLC

Global Retirement Partners LLC grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,798 shares of the medical research company’s stock after purchasing an additional 112 shares during the period. Global Retirement Partners LLC’s holdings in IQVIA were worth $2,122,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the 3rd quarter valued at about $27,000. Avior Wealth Management LLC boosted its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares in the last quarter. Synergy Asset Management LLC bought a new position in shares of IQVIA during the 4th quarter valued at about $33,000. Assetmark Inc. lifted its stake in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares in the last quarter. Finally, Concord Wealth Partners purchased a new stake in IQVIA during the third quarter valued at about $57,000. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In related news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Trading Down 1.3 %

NYSE:IQV opened at $194.01 on Friday. The stock’s 50 day moving average price is $199.86 and its 200 day moving average price is $216.95. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a market capitalization of $34.16 billion, a P/E ratio of 25.87, a P/E/G ratio of 1.98 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.86 EPS for the current fiscal year.

Analysts Set New Price Targets

IQV has been the subject of a number of analyst reports. UBS Group reduced their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Stifel Nicolaus reduced their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.